4Martel CL, Gumerlock PH, Meyers FJ, et al. Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev,2003, 29 (3): 171-187.
5Hessels D, Verhaegh GW, Schalken JA, et al. Applicability of biomarkers in the early diagnosis of prostate cancer. Expert Rev Mol Diagn, 2004, 4 (4): 513-526.
6Graner LS, Lawler KD, Marignca JL, et al. Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM'protein in the LNCaP prostatic carcinoma cell line. Cancer Res, 1998, 58(21): 4787-4789.
7Basso D, Fogar MG, Piva MG, et al. Total PSA, free PSA/total PSA ratio, and molecular PSA detection in prostate cancer: which is clinically effective and when? Urology, 2000, 55 (5): 710-715.
8Chu DC, Chuang CK, Liou YF, et al. The use of real-time quantitative PCR to detect circulating prostate-specific membrane antigen mRNA in patients with prostate carcinoma. Ann N Y Acad Sci, 2004, 1022 (4):157-162.
9Nam RK, Dianeondis EP, Toi A, et al. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J Clin Oncol, 2000, 18 (5):1036-1042.
10Magklara A, Scorilas A, Catalona WJ, et al. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic byperplasia in patients with moderately increased total PSA. Clin Cbem, 1999, 45 ( 11 ) :1961-1966.
7Amin MB, Ro JY, Ayala AG. Prostatic intraepithelial neoplasia: relationship to adenocarcinoma of prostate. Pathol Annu, 1994,29:1-30.
8Sentinellis. Mucins in prostatic intraepithelial neoplasia and prostatic carcinoma. Histopathology, 1993,22:271-274.
9Tamboli P, Amin MB, Schultz DS, et al. Comparative analysis of nuclear proliferative index ( Ki-67 ) in benign prostate, prostatic intraepithelial neoplasia and prostatic carcinoma. Mod Pathol, 1996, 9 :1015-1019.
10Tamboli P, Amin MB ,Xu H J, et al. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia:in comparison with prostatic adenocarcinoma and benign prostate. Mod Pathol, 1998.11:247-252.
3KAWAI M, OKAJIMA K, KOBAYASHI K, et al. Combined use of PSA density and free to total PSA ratio for cancer detection from patients with PSA elevations [J]. Hinyokika Kiyo (日文), 2006, 52 (2): 113- 117.
4LOEB S, GONZALEZ C M, ROEHL K A, et al. Patho- logical characteristics of prostate cancer detected through prostate specific antigen based screening [ J ]. J Urol, 2006, 175 (3): 902-906.
5Cooner WH ,Mosley BR ,Rutherford CL,et al. Clinical application of transrectal ultrasonography and prostate specific antigen in the search for prostatecancer. J Urol ,1988 ,139:758-761
6Thomas A. Stamey, Mitcholl caldwell, John E. Mcneal,et al. The prostate spocific antigen era in the united states is over for prostate cancer:What happen inthe last 20 years?2004,172(10):1297-1301
7Watson RW, Schalken JA. Future opportunities for the diagnosis and treatment of prostate cancer. Prostate Cancer Prostatic Dis, 2004, 7 (1):S8-S13
8HELPAP B. The significance of the P504S expression pattern of high-grade prostatic intraepithelial neoplasia (HGPIN) with and without adenocarcinoma of the prostate in biopsy and radical prostatectomy specimens[J]. Virchows Arch, 2006, 448 (4) : 480- 484.
9LOEB S, GONZALEZ C M, ROEHL K A, et al. Pathological characteristics of prostate cancer detected through prostate specific antigen based screening[J]. J Urol, 2006, 175 (3 Pt 1 ) : 902- 906.
10YANG W J, LEE D H, CHUNG B H, et al. Detection rate of prostate cancer on biopsy according to serum prostate-specific antigen in Korean men: a multicenter study[ J ]. Urology, 2006, 67 (2) : 333-336.
